Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
The Patient Choice Act - HR 2090 To obtain provisional approval of drugs in clinical trials for patients with terminal and life threatening illnesses. This legislation would allow individuals to obtain drugs outside of the scope of Phase I and Phase II clinical trials.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FIGHT TO LIVE via TAYLOR, SYLLA & AGIN, LLP
2013 · third_quarter · Q3
The Patient Choice Act - HR 2090 To obtain provisional approval of drugs in clinical trials for patients with terminal and life threatening illnesses. This legislation would allow individuals to obtain drugs outside of the scope of Phase I and Phase II clinical trials.
FIGHT TO LIVE via TAYLOR, SYLLA & AGIN, LLP
2013 · third_quarter · RR
Source: Senate LDA
Patient Choice Act of 2013, FDA provisional approval for drugs with adequate safety profiles.
Patient Choice Act of 2013, FDA provisional approval for drugs with adequate safety profiles.